John Vandermosten

Rani Therapeutics reports 2Q & recent achievements:
*Chugai collab
*RT114 data & announced Ph1 start in 2H25
*Capital raises
*30Jun cash at $10.2mm
$RANI
ir.ranitherapeutics.com/news-release...

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its propri...

Protalix Biotherapeutics to report 2Q on 14Aug
*Call at 8:30 am ET that morning
$PLX
finance.yahoo.com/news/protali...

GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine GEO-CM04S1 Offers Solution to Overcome HHS-Cited mRNA Deficiencies - Potentially Offering Broader, More Durable Protection ATLANTA, GA - August 7, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX...

Following statements by RFK as Secretary of HHS on eliminating mRNA vaccine, GeoVax highlights its multi-antigen MVA vaccine candidate as an attractive alternative. $GOVX CEO Dodd notes that its Covid vaccine align with HHS priorities.
finance.yahoo.com/news/geovax-...

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program Conference Call Scheduled for 8:30 AM EDT Today, August 7, 2025SEATTLE and VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage speci...

Achieve Life Sciences reports 2Q
Will host call @ 8:30 am ET
$ACHV
finance.yahoo.com/news/achieve...

Ligand Pharmaceuticals reports 2Q
*Revs $47.6mm vs our $44
*Core adj EPS $1.60 vs our $1.58
*Rev guidance up $20-25mm
*EPS up 70-75c
*Call @ 8:30 am ET
$LGND
investor.ligand.com/news-and-eve...

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patientsKANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cing...

Cingulate submits NDA to #FDA for CTx-1301, an active day formulation of dexmethylphenidate for #ADHD.
*31Jul submission
*Acceptance expected before end of Sept
*We see PDUFA in 2Q26
$CING
finance.yahoo.com/news/cingula...

@lantheus.bsky.social reports 2Q25
*Revs $378mm
*adj EPS $1.57
*Rev guidance reduced by 4-5% & EPS by $1
*Call @ 8 am ET
$LNTH
lantheusholdings.gcs-web.com/news-release...

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025 JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable produ...

Dyadic Applied BioSolutions to report 2Q25 on 13Aug
*Call @ 5 pm ET
$DYAI
finance.yahoo.com/news/dyadic-...

$70M Strategic Injection
$LGND: $40M w/ $35M in royalty‑based capital & $5M in equity
$MDT: $30M w/ $10M equity & $20M convertible note tied to FDA approval
$$$ supports expansion into leadless pacemaker integration with AVIM therapy

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed • Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to in...

Ligand Pharmaceuticals along with $MDT to invest in Orchestra BioMed ($OBIO) & its atrioventricular interval modulation therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients
$LGND
finance.yahoo.com/news/ligand-...

GeoVax accelerates GEO-MVA vaccine development on the heels of international spread of Clade I Mpox cases.
$GOVX
geovax.com/investors/pr...

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock - Dyadic JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, ...

Yesterday Dyadic announced a common stock offering. $DYAI priced 6.05mm shares today @ 95c.
Gross proceeds of $5.75mm expected.
1Aug closing.
dyadic.com/update-dyadi...

Spectral AI Schedules 2025 Second Quarter Financial Results and Conference Call DALLAS, July 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System and focused on medical diagnostics for faster and mor...

Spectral AI to report 2Q results 12Aug
Call @ 5 pm ET
$MDAI
finance.yahoo.com/news/spectra...

It's the summer of submissions....
youtu.be/sekidbRmA0Q

Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301 PDUFA Fee Waiver comes Days before Planned Submission of New Drug ApplicationKANSAS CITY, Kan., July 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing i...

Cingulate announces receipt of NDA filing waver from #FDA.
Non waiver fee for NDA with clinical data is ~$4mm.
CTx-1301 filing expected before month end.
$CING
finance.yahoo.com/news/cingula...

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177 On track to complete enrollment of the first cohort of Pha...

Radiopharm Theranostics reports FY25 results
$RADX
finance.yahoo.com/news/radioph...

Further discussion of DehydraTECH side effect profile by $LEXX
finance.yahoo.com/news/lexaria...

GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology Study Aims to Validate Thermostable, Self-Administered MVA-Vaccine Platform for Pandemic Preparedness and Global Immunization ATLANTA, GA - July 28, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GO...

GeoVax announces program to use the Vaxxas Microarray Patch for vaccine delivery.
Approach is particularly useful in areas with limited medical infrastructure.
$GOVX
finance.yahoo.com/news/geovax-...

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01) Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to initiate first-in-human study of RV-01 in solid tumors in 4Q25...

FDA grants Radiopharm Theranostics IND clearance to start RV01 trial targeting solid tumors with Lu177-B7H3 mAb.
2H25 expected Ph1 start.
$RADX
finance.yahoo.com/news/radioph...

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient rete...

Lexaria Biosciences highlights the GLP-1 agonist side effect profile of DehydraTECH formulated GLP-1s vs approved versions of the drug. An important hurdle to patient use are the unpleasant associated side effects. DehydraTECH may help.
$LEXX
finance.yahoo.com/news/lexaria...

GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination ATLANTA, GA - July 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GO...

GeoVax will advance its cancer therapy Gedeptin into primary, resectable head and neck squamous cell carcinoma with pembrolizumab. This move was prompted by KEYNOTE689 results where pembro demonstrated improvement in HNSCC.
$GOVX
finance.yahoo.com/news/geovax-...

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025 SEATTLE and VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development a...

Achieve Life Sciences to report 2Q results 7Aug
*call @ 8:30 am ET
$ACHV
finance.yahoo.com/news/achieve...

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 202...

Ligand Pharmaceuticals to report 2Q results 7Aug
*Call @ 8:30 am ET
$LGND
finance.yahoo.com/news/ligand-...

Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, A...

@lantheus.bsky.social to report 2Q25 results on 6Aug.
Call @ 8 am ET
$LNTH
finance.yahoo.com/news/lantheu...

GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025 GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA - July 22, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and...

GeoVax to report 2Q25 results on Monday, July 28.
Call @ 4:30 pm ET.
$GOVX
finance.yahoo.com/news/geovax-...

YouTube video by Unboxing Biotech Dr. Chris Lewis Highlights DeepView's Strengths

Dr Chris Lewis authored an article published in the journal Burns detailing the findings from @Spectral_MDAI’s trial evaluating DeepView burn diagnostic. Dr Lewis reviews the risks of underdiagnosing and overdiagnosing burns.
$MDAI
youtu.be/mbc0isP30iE

Radiopharm Theranostics appoints Dr Oliver Sartor to $RADX scientific advisory board.
He earned his MD & was professor @ the prestigious & distinguished Tulane University in NOLA. Go Green Wave.
mailchi.mp/d1f30af15a95...

Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisitio...

@lantheus.bsky.social completes Life Molecular Imaging acquisition & appoints Dr Ludger Dinkelborg as R&D head.
$LNTH gains β amyloid imaging agent Neuraceq.
finance.yahoo.com/news/lantheu...

GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company de...

GeoVax revenue from its Mpox & smallpox vaccine could be sooner than expected based on EMA feedback.
A Ph3 immuno-bridging study may provide sufficient data to support an MAA under the EU's centralized procedure.
$GOVX
finance.yahoo.com/news/geovax-...

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its propri...

Protalix BioTherapeutics will transition to a new CFO over the next month. Gilad Mamlok will take the financial reins of the company on 24Aug.
$PLX
finance.yahoo.com/news/protali...